共 50 条
- [46] Market Entry of Biosimilar Low-Molecular-Weight Heparins in Europe: Opportunities and Challenges SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2013, 39 (03): : 250 - 257
- [48] Changes in Medicare Part B Spending for Biologic Drugs After Biosimilar Entry Into the Market JAMA HEALTH FORUM, 2021, 2 (09): : E212634
- [49] Operating performance following open market share repurchase announcements JOURNAL OF ACCOUNTING & ECONOMICS, 2005, 39 (03): : 411 - 436